Research programme: bone disease peptide therapeutics - Alize Pharma

Drug Profile

Research programme: bone disease peptide therapeutics - Alize Pharma

Alternative Names: I-HBD1 analogs - Alize Pharma

Latest Information Update: 29 Sep 2016

Price : $50

At a glance

  • Originator University of Maine; University of North Carolina at Chapel Hill
  • Developer Alize Pharma; New Paradigm Therapeutics
  • Class Peptides
  • Mechanism of Action Insulin-like growth factor binding protein 2 modulators; Osteoblast stimulants; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 01 May 2016 Preclinical trials in Postmenopausal osteoporosis in USA (Parenteral)
  • 04 Dec 2014 Preclinical trials in Osteoporosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top